Hepatic stellate cells in hepatitis C patients: Relationship with liver iron deposits and severity of liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 1, 2004, Pages 91-98

  Martinelli, Ana L C ^a   Ramalho, Leandra N Z ^a   Zucoloto, Sergio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic hepatitis C; Glial fibrillary acid protein; Hepatic stellate cells; Iron deposits; Smooth muscle alpha actin

Indexed keywords

ALPHA ACTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IRON;

ADULT; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IRON STORAGE; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; MALE; PRIORITY JOURNAL; STELLATE CELL;

EID: 1642520853     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03255.x     Document Type: Article

References (41)

1. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-13.
2. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995; 22: 449-56.
3. Piperno A, D'alba R, Fargion S et al. Liver iron concentration in chronic viral hepatitis: a study of 98 patients. Eur. J. Gastroenterol. Hepatol. 1995; 7: 1203-8.
4. Piperno A, Sampietro M, D'alba R. et al. Iron stores, response to alpha-interferon therapy, and effect of iron depletion in chronic hepatitis C. Liver 1996; 16: 248-54.
5. Riggio O, Montagnese F, Fiore P et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am. J. Gastroenterol. 1997; 92: 1298-301.
6. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J. Hepatol. 1996; 25: 633-8.
7. Smith BC, Grove J, Guzail MA et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695-9.
8. Martinelli ALC, Franco RF, Villanova MG et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol. 1999; 102: 152-6.
9. Negro F, Samil K, Brandt LR et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J. Med. Virol. 2000; 60: 21-7.
10. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
11. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. In: Gish R, ed. Clinics in Liver Disease: Current and Future Treatment Therapies for Liver Disease. Philadelphia: W.B. Saunders Company, 2001; 315-34.
12. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. In: Herrera JL, ed. Clinics in Liver Disease: Pathophysiology of Liver Disease. Philadelphia: W.B. Saunders Company, 2000; 409-29.
13. Saikada I, Nagatomi A, Hironaka K, Uchida K, Kiwamu O. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am. J. Gastroenterol. 1999; 94: 489-96.
14. Clouston AD, Jonsson JR, Purdie DM et al. Steatosis and chronic hepatitis C. analysis of fibrosis and stellate cell activation. J. Hepatol. 2001; 34: 314-20.
15. Khan MA, Poulos JE, Brunt EM et al. Hepatic alpha-smooth muscle actin expression in hepatitis C patients before and after interferon therapy. Hepato-Gastroenterology 2001; 48: 212-5.
16. Rigamonti C, Andorno S, Maduli E et al. Iron, hepatic cells and fibrosis in chronic hepatitis C. Eur. J. Clin. Invest. 2002; 1: 28-35.
17. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
18. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
19. Sciot R, Van Eyken P, Facchetti F et al. Hepatocellular transferrin receptor expression in secondary siderosis. Liver 1989; 9: 52-61.
20. Zimmerman H, Fellay M, Zimmerman A. Hepatic stellate cell (Ito cells) but not collagen IV may partially be responsible for lower pressure after reversing secondary biliary cirrhosis in the rat. J. Hepatol. 1997; 26: 158-66.
21. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative haemochromatosis mutations. J. Med. Genet. 1997; 34: 275-8.
22. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996; 13: 399-408.
23. Beutler E, Gelbert T, West C et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol. Dis. 1996; 22: 187-94.
24. Aguilar Martinez P, Biron C, Blanc F et al. Compound heterozygotes for hemochromatosis gene mutations: May they help to understand the pathophysiology of the disease? Blood Cells Mol. Dis. 1997; 23: 269-76.
25. Martinelli ALC, Zago MA, Roselino AMF et al. Porphyria cutanea tarda in Brazilian patients. Association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am. J. Gastroenterol. 2000; 95: 3516-21.
26. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis C282Y mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321-3.
27. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
28. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al. Porphyria cutanea tarda, hepatitis C and HFE gene mutations in North America. Hepatology 1998; 27: 1661-9.
29. Stuart KA, Busfield F, Jazwinsk EC et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J. Hepatol. 1998; 28: 404-9.
30. Hézode C, Cazeneuve C, Coué O et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol. 1999; 31: 979-84.
31. Erhardt A, Maschner-Olberg A, Mellenthin C et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozigosity are independent risk factors for liver fibrosis and cirrhosis. J. Hepatol. 2003; 38: 335-42.
32. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003; 124: 318-26.
33. Brunt EM, Olynk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am. J. Gastroenterol. 2000; 95: 1788-93.
34. Maher JJ. Interactions between hepatic stellate cells and the immune system. Sem. Liver Dis. 2001; 21: 417-36.
35. Marra F, Efsen E, Romanelli RG et al. Ligands of peroxisome proliferator-activated receptor gamma modulate fibrogenic and proinflammatory actions in hepatic stellate cell. Gastroenterology 2000; 119: 466-78.
36. Nieto N, Friedman SL, Greenwel P, Cederbaum AL. CYPeE1-mediate oxidative stress induces collagen type 1 expression in rat hepatic stellate cells. Hepatology 1999; 30: 987-96.
37. Bonkovsky HL, Troy N, McNeal K et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J. Hepatol. 2002; 37: 848-54.
38. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J. Hepatol. 2002; 36: 687-91.
39. Yano M, Hayashi H, Wakusawa S et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am. J. Gastroenterol. 2002; 97: 133-7.
40. Guido M, Rugge M, Chemello L et al. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J. Hepatol. 1996; 24: 301-7.
41. Cortez-Pinto H, Baptista A, Camilo ME, Moura MC. Hepatic stellate cell activation occurs in non-alcoholic steatohepatitis. Hepato-Gastroenterology 2001; 48: 87-90.